Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | GPR119 | Q8TDV5 | 18/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128834 | 0.90 | CYP2C9 (0.60) | CYP2C9CYP3A4GPR119KCNH2 | |
| SCHEMBL303668 | 0.89 | CYP2C9 (0.80) | CYP2C9CYP3A4GPR119KCNH2 | |
| SCHEMBL10151300 | 0.87 | CYP2C9 (0.58) | CYP2C9CYP3A4GPR119KCNH2 | |
| SCHEMBL11913127 | 0.85 | GPR119 (0.51) | CYP2C9CYP3A4GPR119KCNH2 | |
| SCHEMBL10137749 | 0.85 | CYP3A4 (0.59) | CYP2C9CYP3A4GPR119ALDH1A1LMNA | |
| SCHEMBL12648956 | 0.81 | GPR119 (0.55) | CYP2C9CYP3A4GPR119 | |
| SCHEMBL12596827 | 0.81 | CYP2C9 (0.51) | CYP2C9CYP3A4GPR119ALDH1A1 | |
| SCHEMBL10137755 | 0.79 | CYP3A4 (0.53) | CYP2C9CYP3A4LMNAMAPTHTT | |
| SCHEMBL10137756 | 0.79 | CYP3A4 (0.51) | CYP2C9CYP3A4GPR119LMNAMAPT | |
| SCHEMBL11913129 | 0.78 | GPR119 (0.51) | CYP2C9GPR119KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476283-B2 | [6,5]—bicyclic GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-02 | — | — | US | disclosed |
| US-20120077826-A1 | [6,5] - BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077826-A1 | [6,5] - BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR139, GPR4 | CYP2C9 767/4885CYP3A4 1283/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.